What is the Pelthos Therapeutics Inc. stock price forecast?

Pelthos Therapeutics Inc. is currently trading at $28.02. View real-time AI analysis on Alpha Lenz.

What is Pelthos Therapeutics Inc. insider trading activity?

View the latest insider trading data for Pelthos Therapeutics Inc. on Alpha Lenz.

What is Pelthos Therapeutics Inc.'s P/E ratio?

View Pelthos Therapeutics Inc.'s valuation metrics on Alpha Lenz.

Pelthos Therapeutics Inc.

NYSE · PTHS

$28.02+1.52(+5.74%)Pre-market

Ask about Pelthos Therapeutics Inc.'s future dividend policy...

Alpha Chat Insight

“Pelthos Therapeutics Inc.'s ROE is -239.6%. Explore profitability and growth together.”

Ask for details →

Company Overview

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing innovative therapeutic products for high unmet patient needs. Its primary function is to develop and launch treatments like ZELSUVMI™, a novel therapeutic product for Molluscum contagiosum infections. Notably, Pelthos Therapeutics leverages its proprietary nitric oxide-based technology platform to address significant medical challenges. The company operates in the pharmaceutical sector, specifically targeting dermatological conditions. With a strong pipeline of potential product candidates, Pelthos aims to deliver impactful treatments to patients across various demographics. Its market significance lies in addressing unmet medical needs through pioneering therapeutic innovations.

CEOMr. Scott M. Plesha

Websitehttps://pelthos.com

SectorHealthcare

IndustryBiotechnology

Employees4

Company Statistics

FY 2025

Profile

N/AMarket Cap

$16.80MRevenue

0.00Shares Out

4Employees

Margins

59.37%Gross

-257.89%EBITDA

-193.09%Operating

-301.91%Pre-Tax

-257.93%Net

Valuation

N/AP/E

N/AP/B

N/AEV/Sales

N/AEV/EBITDA

N/AP/FCF

Growth (CAGR)

N/ARev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-65.75%ROA

-239.55%ROE

-72.39%ROIC

Financial Health

$17.97MCash & Cash Equivalents

$73.54MNet Debt

235.37%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Pelthos Therapeutics Inc.'s ROE is -239.6%. Explore profitability and growth together.”

Ask for details →

Frequently Asked Questions

Pelthos Therapeutics Inc. (ticker: PTHS) is a company listed on NYSE in the Healthcare sector (Biotechnology). It has approximately 4 employees.

The current price is $28.02 with a P/E ratio of -x and P/B of -x.

ROE is -239.55% and operating margin is -193.09%. Annual revenue is $17M.